SAVA vs. INVA, IRWD, TYRA, BCYC, ARQT, OCUL, COLL, LQDA, VRNA, and CNTA
Should you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Innoviva (INVA), Ironwood Pharmaceuticals (IRWD), Tyra Biosciences (TYRA), Bicycle Therapeutics (BCYC), Arcutis Biotherapeutics (ARQT), Ocular Therapeutix (OCUL), Collegium Pharmaceutical (COLL), Liquidia (LQDA), Verona Pharma (VRNA), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical preparations" industry.
Cassava Sciences (NASDAQ:SAVA) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.
In the previous week, Cassava Sciences had 3 more articles in the media than Innoviva. MarketBeat recorded 6 mentions for Cassava Sciences and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.51 beat Cassava Sciences' score of 0.29 indicating that Innoviva is being referred to more favorably in the news media.
Cassava Sciences has a beta of -0.38, meaning that its stock price is 138% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.
Innoviva has a net margin of 58.21% compared to Cassava Sciences' net margin of 0.00%. Innoviva's return on equity of 28.94% beat Cassava Sciences' return on equity.
Cassava Sciences presently has a consensus target price of $131.00, indicating a potential upside of 466.61%. Given Cassava Sciences' higher possible upside, equities research analysts plainly believe Cassava Sciences is more favorable than Innoviva.
38.0% of Cassava Sciences shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 9.0% of Cassava Sciences shares are owned by insiders. Comparatively, 1.4% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Innoviva has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Innoviva received 200 more outperform votes than Cassava Sciences when rated by MarketBeat users. However, 66.43% of users gave Cassava Sciences an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
Summary
Innoviva beats Cassava Sciences on 11 of the 16 factors compared between the two stocks.
Get Cassava Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cassava Sciences Competitors List
Related Companies and Tools
